SPRR2A and psoriasis: Specific "IL-12/23RA include ustekinumab, a fully human monoclonal antibody that targets both IL-23 and IL-12; mirikizumab, a monoclonal antibody targeting the p19 subunit of IL-23, shown to reduce inflammation and improve symptoms; guselkumab, another monoclonal antibody that selectively targets the p19 subunit of IL-23, primarily studied in psoriasis; and risankizumab, which binds to the p19 subunit of IL-23 and has demonstrated promising results in UC trials, with potential for inducing long-term remission.33